Kelly E Dooley

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 37

Top Topics

Multidrug Resistant

Pulmonary Tuberculosis

Human Immunodeficiency Virus

Top Venues

American journal of respiratory and critical care medicine

Antimicrobial agents and chemotherapy

PLOS global public health

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick Peter John Phillips, Payam Nahid, Susan E Dorman, Ekaterina V Kurbatova, William C Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr, Nicole E Brown, Melissa L Engle, Nguyen Viet Nhung, Pheona Nsubuga, Andreas H Diacon, Kelly E Dooley, Richard E Chaisson, Susan Swindells, Radojka M Savic, null null
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial. American journal of respiratory and critical care medicine (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley, null null
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial. American journal of respiratory and critical care medicine (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley, null null
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial. American journal of respiratory and critical care medicine (2024)
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick Peter John Phillips, Payam Nahid, Susan E Dorman, Ekaterina V Kurbatova, William C Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr, Nicole E Brown, Melissa L Engle, Nguyen Viet Nhung, Pheona Nsubuga, Andreas H Diacon, Kelly E Dooley, Richard E Chaisson, Susan Swindells, Radojka M Savic, null null
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial. American journal of respiratory and critical care medicine (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Keri Geiger, Amita Patil, Chakra Budhathoki, Kelly E Dooley, Kelly Lowensen, Norbert Ndjeka, Jacqueline Ngozo, Jason E Farley
Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. PLOS global public health 4 (5) (2024)
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick Peter John Phillips, Payam Nahid, Susan E Dorman, Ekaterina V Kurbatova, William C Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr, Nicole E Brown, Melissa L Engle, Nguyen Viet Nhung, Pheona Nsubuga, Andreas H Diacon, Kelly E Dooley, Richard E Chaisson, Susan Swindells, Radojka M Savic, null null
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial. American journal of respiratory and critical care medicine (2024)
Keri Geiger, Amita Patil, Chakra Budhathoki, Kelly E Dooley, Kelly Lowensen, Norbert Ndjeka, Jacqueline Ngozo, Jason E Farley
Relationship between HIV viral suppression and multidrug resistant tuberculosis treatment outcomes. PLOS global public health 4 (5) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley, null null
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial. American journal of respiratory and critical care medicine (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick Peter John Phillips, Payam Nahid, Susan E Dorman, Ekaterina V Kurbatova, William C Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr, Nicole E Brown, Melissa L Engle, Nguyen Viet Nhung, Pheona Nsubuga, Andreas H Diacon, Kelly E Dooley, Richard E Chaisson, Susan Swindells, Radojka M Savic, null null
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial. American journal of respiratory and critical care medicine (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American journal of respiratory and critical care medicine 210 (3) (2024)
Kamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, Caryn Upton, Soyeon Kim, Ashley McKhann, Laura Moran, Lubbe Wiesner, Florian von Groote-Bidlingmaier, Philip Marzinek, Naadira Vanker, Joseph Yvetot, Samuel Pierre, Susan L Rosenkranz, Susan Swindells, Andreas H Diacon, Eric L Nuermberger, Paolo Denti, Kelly E Dooley, null null
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial. American journal of respiratory and critical care medicine (2024)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy (2023)
Ryan T Jarrett, Yuri van der Heijden, Matthew S Shotwell, Violet Chihota, Mark A Marzinke, Richard E Chaisson, Kelly E Dooley, Gavin J Churchyard
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. Antimicrobial agents and chemotherapy 67 (2) (2023)
Allan Kengo, Ruth Nabisere, Kamunkhwala Gausi, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Kelly E Dooley, Derek James Sloan, Paolo Denti, Christine Sekaggya-Wiltshire
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin. Antimicrobial agents and chemotherapy (2023)
Veronique R de Jager, Nikhil Gupte, Silvia Nunes, Grace L Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E Dorman, Ahmed A Abulfathi, Caryn M Upton, Alan Faraj, Eric L Nuermberger, Gyanu Lamichhane, Elin M Svenson, Ulrika S H Simonsson, Andreas H Diacon, Kelly E Dooley
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. American journal of respiratory and critical care medicine 205 (10) (2022)
Lénaïg Tanneau, Mats O Karlson, Susan L Rosenkranz, Yoninah S Cramer, Justin Shenje, Caryn M Upton, Joel Morganroth, Andreas H Diacon, Gary Maartens, Kelly E Dooley, Elin M Svenson
Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens. Clinical pharmacology and therapeutics 112 (4) (2022)
Aida Nakayiwa Kawuma, Roeland E Wasmann, Kelly E Dooley, Marta Boffito, Gary Maartens, Paolo Denti
Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrobial agents and chemotherapy 66 (6) (2022)
Kelly E Dooley, Bronwyn Hendricks, Nikhil Gupte, Grace Barnes, Kim Narunsky, Colleen Whitelaw, Tanya Smit, Elisa H Ignatius, Adine Friedman, Susan E Dorman, Rodney Dawson, null null
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results. American journal of respiratory and critical care medicine (2022)
Rokeya Tasneen, Andrew Garcia, Paul J Converse, Matthew D Zimmerman, Veronique Anne Dartois, Ekaterina Kurbatova, Andrew A Vernon, Wendy Carr, Jason E Stout, Kelly E Dooley, Eric L Nuermberger
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy 66 (4) (2022)
Olumide Martins, Jin Lee, Amit Kaushik, Nicole C Ammerman, Kelly E Dooley, Eric L Nuermberger
In Vitro Activity of Bedaquiline and Imipenem against Actively Growing, Nutrient-Starved, and Intracellular Mycobacterium abscessus. Antimicrobial agents and chemotherapy 65 (12) (2021)
Elisa H Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, Nikhil Gupte, Kim Narunsky, Lubbe Wiesner, Grace Barnes, Rodney Dawson, Kelly E Dooley, Paolo Denti
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrobial agents and chemotherapy 65 (2) (2021)
Solomon P le Roux, Caryn M Upton, Naadira Vanker, Kelly E Dooley, Andreas H Diacon, null null
Resistance-Conferring Mycobacterial Mutations and Quantification of Early Bactericidal Activity. American journal of respiratory and critical care medicine 203 (5) (2021)
Kelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, Xin Sun, Richard Hafner, Susan L Rosenkranz, Elisa H Ignatius, Eric L Nuermberger, Laura Moran, Kathleen Donahue, Susan Swindells, Naadira Vanker, Andreas H Diacon
Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. American journal of respiratory and critical care medicine 201 (12) (2020)
Kelly E Dooley, Debra Hanna, Vidya Mave, Kathleen Eisenach, Radojka M Savic
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology. PLoS medicine 16 (7) (2019)
Kelly E Dooley
High-Dose Rifampin: Shall We Be Bolder? American journal of respiratory and critical care medicine 198 (5) (2019)
Dalin Rifat, Brendan Prideaux, Radojka M Savic, Michael E Urbanowski, Teresa L Parsons, Brian M Luna, Mark A Marzinke, Alvaro A Ordonez, Vincent P DeMarco, Sanjay K Jain, Veronique Anne Dartois, William R Bishai, Kelly E Dooley
Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Science translational medicine 10 (435) (2019)